Aelis Farma
Bordeaux
About Aelis Farma
Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $34.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2024)
- Ticker: epa:AELIS
- Website: aelisfarma.com
- Phone: +33 5 57 57 37 70
Industries & Categories
Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aelis-farma-71931 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.